TY - JOUR AU - Mehanna, Joe AU - Haddad, Fady GH. AU - Eid, Roland AU - Lambertini, Matteo AU - KouriƩ, Hampig Raphaƫl PY - 2018 TI - What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab? JF - Translational Cancer Research; Vol 7, No 6 (December 30, 2018): Translational Cancer Research Y2 - 2018 KW - N2 - Breast cancer is the most common malignancy among women worldwide and the leading cause of cancer death in many countries (1). In around 20% to 25% of breast cancer cases, there is an overexpression of HER2 or an amplification of its gene (HER2-positive subtype); HER2 is a transmembrane receptor implicated in tumor replication, invasion and dissemination (2). HER2-positive breast cancer is characterized by a worse prognosis, aggressive disease, higher mitotic index, worse nuclear grade and lymph nodes positivity (3). UR - https://tcr.amegroups.org/article/view/24188